Peptide Comparison
GHK vs Klow
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
GHK and Klow share the matrikine class and carry roughly equivalent evidence (Preclinical + Cosmetic / Anecdotal). On the catalogued data layer GHK has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; GHK's evidence base is currently denser.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| GHK | Klow | |
|---|---|---|
| Class | Matrikine tripeptide; signaling/reparative | Four-component regenerative blend (Glow + KPV anti-inflammatory) |
| Drug class | Tissue Repair | Tissue Repair |
| Mechanism | Modulates expression of hundreds of genes related to tissue repair; copper transport | Composite formulation layering matrikine signalling, cytoprotection, actin regulation, and NF-kB suppression: GHK-Cu (copper-peptide matrikine activating ~4,000 wound-healing / collagen-elastin genes), BPC-157 (angiogenesis via VEGFR2 + epithelial / tendon repair), TB-500 (actin sequestration + stem-cell mobilisation + anti-fibrotic), KPV (alpha-MSH-derived tripeptide inhibiting NF-kB at mucosal epithelium). Klow is essentially the Glow blend plus KPV for an inflammation-suppression arm. |
| Route | Topical / SC | SC injection |
| Half-life | Minutes (plasma) | Composite: hours to days per component (TB-500 longest) |
| Dosage (research) | 1-5 mg daily topical/SC (research) | Typical SC protocols deliver ~250 mcg of each component daily (per-component basis from a combined-mg vial) for 4-8 week loading cycles. Confirm vial composition with vendor before computing per-component dose |
| Evidence tier | Preclinical + Cosmetic | Anecdotal |
| Research depth | 163 indexed | — |
| Availability | Research | Compounding Restricted |
| Reported risks | Less bioavailable than GHK-Cu; limited injectable human trials | No human-trial data on the combined formulation; each component carries its own risk profile (TB-500 WADA-banned, theoretical pro-proliferative concerns; copper accumulation at chronic GHK-Cu doses); injection-site reactions; meaningful batch-to-batch composition variability across compounders |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick GHK or Klow?
GHK and Klow share the matrikine class and carry roughly equivalent evidence (Preclinical + Cosmetic / Anecdotal). On the catalogued data layer GHK has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; GHK's evidence base is currently denser.
What is the difference between GHK and Klow?
GHK is classed as Matrikine tripeptide; signaling/reparative; Klow is classed as Four-component regenerative blend (Glow + KPV anti-inflammatory). Reported mechanism: GHK, Modulates expression of hundreds of genes related to tissue repair; copper transport; Klow, Composite formulation layering matrikine signalling, cytoprotection, actin regulation, and NF-kB suppression: GHK-Cu (copper-peptide matrikine activating ~4,000 wound-healing / collagen-elastin genes), BPC-157 (angiogenesis via VEGFR2 + epithelial / tendon repair), TB-500 (actin sequestration + stem-cell mobilisation + anti-fibrotic), KPV (alpha-MSH-derived tripeptide inhibiting NF-kB at mucosal epithelium). Klow is essentially the Glow blend plus KPV for an inflammation-suppression arm. Reported half-life: GHK, Minutes (plasma); Klow, Composite: hours to days per component (TB-500 longest). Routes in published studies: GHK, Topical / SC; Klow, SC injection.
Which has stronger evidence, GHK or Klow?
Klow has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. GHK is graded Preclinical + Cosmetic, with 8 cited sources on its reference page and 163 indexed studies. Klow is graded Anecdotal, with 4 cited sources on its reference page.
Which is more accessible, GHK or Klow?
Neither GHK nor Klow is an FDA-approved drug. Catalog status: GHK, Research; Klow, Compounding Restricted.
Are GHK and Klow ever combined?
GHK and Klow appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…